GSK and Pfizer launch joint HIV collaboration
Following the initial announcement in April 2009 of a collaboration between GlaxoSmithKline and Pfizers to create a new specialist company dedicated to HIV, called ViiV Healthcare was launched on 3 November 2009. GSK holds an 85% interest in ViiV Healthcare and Pfizer holds 15%.
ViiV Healthcare has 10 licensed medicines which generated £1.6 billion in 2008 and a pipeline of seven investigative compounds, including five in phase II development and 10 other potential molecules to develop new HIV treatments.
GSK previous Positive Action programme will be at the core of ViiV Healthcares partnership programmes, supporting local communities impacted by HIV/AIDS globally.
The ViiV web site provides an overview of the new company and its current activities, including Positive Action and Community Partnerships, the R&D pipeline, initiatives to improve access, and corporate governance:
Company Press Release: ViiV Healthcare – a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV. (3 November 2009).